Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06839820 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Infliximab Infusion Rates in Pediatric Inflammatory Bowel Disease

Study acronym: iRAPID
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Apr 2026 to Dec 2026 Trial status: Recruiting to Active, Not Recruiting · Site details revisedv3 Show 2 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
  2. Eligibility criteria shortened, about 24 wordsv2 See this version in full on ClinicalTrials.gov ↗
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
OBJECTIVES OF THE STUDY 1. Investigate whether there are just as few infusion reactions with infliximab infusions of 60 min and 30 min. 2. Investigate patient and nurse satisfaction with infusions of 60 min and 30 min. 3. Investigate resource use in terms of total length of stay and use of nursing resources.
Trial Details
NCT Number NCT06839820
Lead Sponsor University Hospital, Akershus
Conditions Infliximab, Infusion, IBD (Inflammatory Bowel Disease), Patient Satisfaction
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov